Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Direct oral anticoagulants (DOACs) are increasingly prescribed, often perceived as safer than warfarin.
• Despite a generally lower bleeding risk, DOACs can cause major bleeding events like diffuse alveolar hemorrhage (DAH).
• Understanding the timing and triggers of DOAC-associated DAH is crucial due to rising DOAC use.

Observation:

• An 80-year-old male on apixaban for atrial fibrillation developed hemoptysis and hypoxic respiratory failure post-procedure.
• Imaging revealed pulmonary infiltrates and ground-glass opacity; bronchoalveolar lavage showed hemosiderin-laden macrophages, confirming DAH.
• Apixaban was stopped, and mechanical ventilation was initiated.

Findings:

• DOAC-associated DAH can occur at any point during treatment, not solely during initial use.
• Bleeding triggers, such as invasive procedures or drug interactions, are frequently associated with DOAC-induced DAH.
• Elderly patients on DOACs, regardless of treatment duration, are susceptible to DAH.

Implications:

• DOAC-associated DAH necessitates careful patient monitoring beyond the initial treatment phase.
• Identifying and managing potential triggers is vital for preventing DOAC-induced DAH.
• This case highlights that DAH is a potential complication of DOACs, irrespective of treatment duration or patient age.